1. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial. Issue 3 (March 2014) Authors: von Tresckow, Bastian; Boell, Boris; Eichenauer, Dennis; Beschorner, Denissa; Knop, Stefan; Goebeler, Maria-Elisabeth; Chemnitz, Jens Marcus; Hallek, Michael; Engert, Andreas; Huebel, Kai Journal: Leukemia & lymphoma Issue: Volume 55:Issue 3(2014:Mar.) Page Start: 695 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Issue 5 (3rd May 2016) Authors: Goebeler, Maria-Elisabeth; Bargou, Ralf Journal: Leukemia & lymphoma Issue: Volume 57:Issue 5(2016:May) Page Start: 1021 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. Issue 11 (18th September 2020) Authors: Viardot, Andreas; Hess, Georg; Bargou, Ralf C.; Morley, Nicholas J.; Gritti, Giuseppe; Goebeler, Maria-Elisabeth; Iskander, Karim; Cohan, David; Zhang, Alicia; Franklin, Janet; Coyle, Luke Journal: Leukemia & lymphoma Issue: Volume 61:Issue 11(2020) Page Start: 2767 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗